Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02564354
Recruitment Status : Completed
First Posted : September 30, 2015
Results First Posted : September 24, 2020
Last Update Posted : September 24, 2020
Sponsor:
Collaborator:
European Commission
Information provided by (Responsible Party):
ProQR Therapeutics

Brief Summary:
Exploratory proof of concept study to determine whether intranasal administration of QR-010 in subjects with cystic fibrosis, homozygous or compound heterozygous for the ΔF508 mutation, can increase the function of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: QR-010 Phase 1

Detailed Description:
This is an open-label, multi-center, exploratory study to estimate the effect of intranasal administration of QR-010 on the nasal mucosa in the restoration of CFTR function, as measured by nasal potential difference (NPD), in the nasal epithelium of adult subjects with CF who are homozygous or compound heterozygous for the ΔF508 CFTR mutation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation
Study Start Date : September 2015
Actual Primary Completion Date : September 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: ΔF508 Homozygous
QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
Drug: QR-010
Single-stranded RNA antisense oligonucleotide in isoosmolar solution

Experimental: ΔF508 Compound Heterozygous
QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
Drug: QR-010
Single-stranded RNA antisense oligonucleotide in isoosmolar solution




Primary Outcome Measures :
  1. Intra-subject Change From Baseline of CFTR-mediated Total Chloride Transport as Measured by Nasal Potential Difference (NPD). [ Time Frame: Baseline, at 2 and 4 weeks, and at 3 weeks post-treatment. ]
    The primary endpoint was the within-subject change from baseline in total chloride transport as measured by NPD, after the Chloride-free+isoproterenol solution (Cl-free+iso), and was based on the average measurements of both nostrils. To provide baseline stability, baseline was defined as the average of the two most recent pre-dose values, where each pre-dose value was the average of two nostrils. A negative change from baseline of Cl-free+iso shows an improvement.


Secondary Outcome Measures :
  1. Number of Subjects With a -6.6 mV or More Negative Change in CFTR-mediated Total Chloride Transport, and After Different Treatment Durations From Baseline Through End of Study. [ Time Frame: 2 and 4 weeks, and at 3 weeks post-treatment. ]
    This analysis is the proportion (amount) of subjects with an average Cl-free+iso actual value of -6.6 mV or more negative after treatment (ie, responders), as measured by NPD and was based on the average measurements of both nostrils. The actual value of -6.6 mV is used to discriminate individuals with CF (>-6.6 mV) from normal individuals (≤ -6.6 mV).

  2. Number of Subjects With a -4 mV or More Negative Change in CFTR-mediated Total Chloride Transport, and After Different Treatment Durations From Baseline Through End of Study. [ Time Frame: 2 and 4 weeks, and at 3 weeks post-treatment. ]
    This analysis is the proportion of subjects with an average Cl-free+iso actual value of -4 mV or more negative after treatment (ie, responders), as measured by NPD and was based on the average measurements of both nostrils. The value of -4 mV is considered a clinically relevant response to treatment based on data from studies of other CFTR therapies.

  3. Intra-subject Change of Sodium Transport as Measured by Nasal Potential Difference (NPD) From Baseline Through End of Study. [ Time Frame: Baseline, at 2 and 4 weeks, and at 3 weeks post-treatment. ]
    This endpoint was the within-subject change in Sodium transport (average Potential Difference prior to perfusion of any solution); this is the average of Potential Difference measured at five sites in the inferior meatus of the nose. A positive change from baseline shows an improvement.

  4. The Mean Change in CFTR-mediated Total Chloride Transport. [ Time Frame: 2 and 4 weeks, and at 3 weeks post-treatment. ]
    The mean change in CFTR-mediated Total Chloride Transport compared to Baseline, per cohort; this is the mean of Potential Difference measured at five sites in the inferior meatus of the nose measured in millivolts (mV). A negative change from baseline shows an improvement.

  5. Number of Subjects Experiencing Serious Adverse Events From Baseline Through End of Study. [ Time Frame: 3 weeks post-treatment. ]
    Number of subjects experiencing serious adverse events from baseline through End of Study.

  6. Number of Subject Discontinuations Due to AEs From Baseline Through End of Study. [ Time Frame: 3 weeks post-treatment. ]
    Number of subject discontinuations due to AEs from baseline through End of Study. No discontinuations occurred.

  7. Number of Subjects With Abnormalities of Laboratory Parameters From Baseline Through End of Study. [ Time Frame: 3 weeks post-treatment. ]
    Number of subjects experiencing at least one abnormality in laboratory parameters (chemistry, hematology and urinalysis) that were reported as treatment emergent adverse event with a relationship to study drug as either possibly, probably or definitely, from baseline through End of Study.

  8. Number of Subjects With Abnormalities of Vital Signs & Oximetry From Baseline Through End of Study. [ Time Frame: 3 weeks post-treatment. ]
    Number of subjects experiencing at least one abnormality vital signs & oximetry that were reported as treatment emergent adverse event with a relationship to study drug as either possibly, probably or definitely, from baseline through End of Study.

  9. Number of Subjects With Abnormalities of Physical Examinations From Baseline Through End of Study. [ Time Frame: 3 weeks post-treatment. ]
    Number of subjects experiencing at least one abnormality in physical examination that were reported as treatment emergent adverse event with a relationship to study drug as either possibly, probably or definitely, from baseline through End of Study.

  10. Changes in Nasal Symptoms (Based on the Nasal Examination Rating Scale - NERS) From Baseline Through End of Study. [ Time Frame: 3 weeks post-treatment. ]
    The NERS was performed by site staff prior to each dose and as part of the NPD procedure; it is a set of scales ranging from 0 (no symptoms) to 3 (most severe symptoms) for assessing the severity of each of the following nasal symptoms, separately for each nostril: mucosal disruption, edema, erythema, polyp, secretions. The range of the total sum is 0-30.

  11. Changes in Nasal Symptoms (Sino-Nasal Outcome Test - SNOT-22) From Baseline Through End of Study. [ Time Frame: 3 weeks post-treatment. ]
    Subjects were asked to score a list of 22 symptoms on the SNOT-22 regarding social and emotional consequences. Outcomes were graded as 0 (no problem), to 5 (problem as bad as it could be). The list included: need to blow nose, sneezing, dripping nose, cough, postnasal drip, dense nasal drip, ear fullness, dizziness, ear pain, facial pain/pressure, difficulty falling asleep, waking at night, lack of a good night's sleep, waking up tired, fatigue, reduced productivity, reduced concentration, frustrated/restless/irritable, sad, embarrassed, decrease in smell and taste, and nasal obstruction. The range of the total sum is 0-110, with higher values indicating worse outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed diagnosis of CF as defined by iontophoretic pilocarpine sweat chloride test (sweat chloride) of > 60 mmol/L
  • Nasal potential difference (NPD) measurement at Screening consistent with CF
  • Confirmation of CFTR gene mutations homozygous or compound heterozygous for the ΔF508 mutation
  • Body mass index (BMI) of ≥ 18 kg/m2
  • Non-smoking for a minimum of 2 years
  • Stable lung function
  • FEV1 ≥40% of predicted normal for age, gender, and height at Screening

Exclusion Criteria:

  • Breast-feeding or pregnant
  • Acute allergy or infection affecting nasal conditions not resolved within 14 days prior Screening
  • Use of lumacaftor or ivacaftor
  • Use of any investigational drug or device
  • Hemoptysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564354


Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
United States, Colorado
National Jewish Health
Denver, Colorado, United States, 80206
United States, Ohio
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Belgium
U.Z. Leuven
Leuven, Belgium, 3000
France
Hopital Necker-Enfants Malades
Paris, France, 75743
Sponsors and Collaborators
ProQR Therapeutics
European Commission
Investigators
Layout table for investigator information
Principal Investigator: John P Clancy, MD Cincinnati Childrens Hospital Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ProQR Therapeutics
ClinicalTrials.gov Identifier: NCT02564354    
Other Study ID Numbers: PQ-010-002
First Posted: September 30, 2015    Key Record Dates
Results First Posted: September 24, 2020
Last Update Posted: September 24, 2020
Last Verified: September 2020
Keywords provided by ProQR Therapeutics:
Cystic Fibrosis
CF
ΔF508
CFTR
QR-010
antisense oligonucleotide
RNA therapy
F508del
NPD
nasal potential difference
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases